Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Post by Sir_Holleron May 04, 2015 8:09pm

185 Views

Post# 23693115

Analyst target

Medicure lists one analyst, Andre Uddin of Mackie Research.

Yahoo! lists one analyst with a $3.50 target and Q2 and full year revenue expectations of $2.5 million and $10.1 million respectively:
https://ca.finance.yahoo.com/q/ae?s=MPH.V

With $3.3 million in Q1 and guidance that expects revenues to continue to grow it looks like MPH smashed his estimates last year. We could see a significant upgrade in the $3.50 price target.

Bullboard Posts

Soma Gold poised to extend profitable track record